True Leaf Plans to Issue New Stocks and Grow Pet Division
True Leaf Medicine International Ltd., a company involved in the hemp and cannabis-based product industry, has filed a preliminary offering circular with the Securities and Exchange Commission (“SEC”). The offering is in accordance with the Regulation A framework, which is open to both accredited and unaccredited investors.
True Leaf has engaged Boustead Securities, LLC as lead underwriter. “Boustead looks forward to working with True Leaf’s team to bring their Regulation A+ offering to investors,” said David Dobkin of Boustead.
“We are pleased to have Boustead leading the effort,” said True Leaf CEO Darcy Bomford. “Their expertise in Regulation A has proven successful in the past.”
The purpose of the filing is to issue new shares of common stock to raise gross proceeds of up to $10 million CAD to help grow the True Leaf Pet division, and to advance the efforts of the True Leaf Medicine division with the goal of becoming a licensed producer of medicinal cannabis in Canada. Once its Regulation A+ offering has been qualified by the SEC, the offering will be made available to the general public to invest in True Leaf.